The invention relates to 1,3-Tellurazolidine-4-carboxylic acid, a stable cyclic telluro-amino acid synthesized from tellurocystine. This novel compound exhibits significant anticancer activity, particularly against breast cancer cell line MCF-7, with enhanced apoptotic effects and minimal toxicity to normal cells. The innovative synthesis method uses diiodomethane for efficient cyclization, avoiding decomposition issues. The compound’s high stability, biocompatibility, and broad therapeutic potential make it a versatile candidate for treating various diseases, including cancer, microbial infections, inflammation, and viral diseases. Additionally, the invention encompasses pharmaceutical compositions and various dosage forms, ensuring flexible and effective administration for diverse medical applications.
Figure (1) illustrates The cytotoxicity assessment of 4,4’-(1,2-Ditellurdiyl)bis(2-aminobutanoic acid) on fibroblast cells (A.)L929 cell line (B.)NIH/3T3 cell line; Image illustrates Cell viability studies on MCF-7 cell line after treating with different concentrations of 4,4’-(1,2-Ditellurdiyl)bis(2-aminobutanoic acid).
Despite the detection and characterization of tellurium (Te)-containing non-natural amino acids such as tellurocysteine, tellurocystine, and telluromethionine in fungi, yeast, and bacteria, there is limited understanding of their bioactivity, particularly in therapeutic contexts.
Notably, there is a gap in the development of Te-containing non-natural amino acids with specific anticancer properties. Given the promising attributes of Te-based compounds, including their structural utility and emerging biomedical applications such as antimicrobial and anticancer activities, there is a critical need to synthesize and evaluate novel Te-containing non-natural amino acids for their potential therapeutic uses.
The technology gives the method to synthesise 4,4’-(1,2-Ditellurdiyl)bis(2-aminobutanoic acid) for the first time, and calls it Tellurohomocystine, which has the following advantages:
- Significant Anticancer Activity: The compound shows potent anticancer effects, particularly against breast cancer cell line MCF-7, with an IC50 value of 7.29±0.27 μg/ml, and enhanced apoptotic activity by arresting the sub G1 phase.
- Biocompatibility: Minimal cytotoxicity observed, making it safer for therapeutic use compared to other tellurium compounds.
- Stability: Enhanced stability compared to tellurocysteine, which forms tellurocystine in the presence of oxygen and is not suitable for anticancer analysis.
- Novel and Efficient Synthesis: Employs environmentally friendly solvents and conditions, reducing the use of toxic organic solvents.
Broad Therapeutic Potential: Beyond anticancer properties, the compound has potential applications as an antimicrobial, anti-inflammatory, antiviral, and immunomodulating agent, making it a versatile candidate for multiple therapeutic uses.
Salient Technical Features:
- Novel Compound: Synthesis of Tellurohomocystine, a Te-containing non-natural amino acid (4,4’-(1,2-Ditellurdiyl)bis(2-aminobutanoic acid)).
- Synthesis Process: Involves steps such as stirring L-Methionine with methanol and iodomethane, refluxing with sodium bicarbonate, treating with hydrobromic acid, reducing Te powder in a degassed solvent using NaBH4, and combining with 2-amino-4-bromobutanoic acid hydrobromide.
- Characterization Techniques: Utilizes multinuclear NMR spectroscopy (1H, 13C, 125Te), high-resolution ESI-MS spectrometry, and elemental analysis.
- Biocompatibility and Anticancer Activity: High cell viability (>80%) with minimal cytotoxicity on normal cells. Shows significant anticancer activity against MCF-7 breast cancer cells with an IC50 of 25.36±0.12 μg/ml and induces apoptosis.
- Pharmaceutical Formulations: Can be formulated into various dosage forms like capsules, tablets, injections, ointments, and powders. Suitable for oral and parenteral administration.
- Enhanced Stability: More stable than tellurocysteine, allowing reliable analysis and therapeutic application.
- Environmentally Friendly Synthesis: Uses non-toxic solvents and conditions, promoting greener chemistry practices.
The prototype includes in vitro cytotoxicity studies of the synthesized compound, 4,4’-(1,2-Ditellurdiyl)bis(2-aminobutanoic acid), on fibroblast cell lines (L929 and NIH/3T3) and its effect on MCF-7 breast cancer cells.
It is currently available for licensing.
3
- With its potent anticancer activity, the compound offers a promising new treatment option for cancer patients, particularly those with resistant forms of cancer like breast cancer. This could improve survival rates and quality of life for many patients.
- By providing new treatments for critical diseases, this technology can help reduce the global burden of illness, particularly in areas with limited access to advanced medical therapies. This can lead to improved health outcomes and increased life expectancy worldwide.
- By utilizing safer, environmentally friendly synthesis methods and reducing the need for toxic solvents, the invention supports greener chemistry practices. This can lead to cost-effective manufacturing processes, reducing the environmental impact of pharmaceutical production and promoting sustainable development in the chemical and pharmaceutical industries.
With its potent anticancer activity, the compound offers a promising new treatment option for cancer patients, particularly those with resistant forms of cancer like breast cancer. Beyond anticancer properties, the compound has potential applications as an antimicrobial, anti-inflammatory, antiviral, and immunomodulating agent, making it a versatile candidate for multiple therapeutic uses.
Geography of IP
Type of IP
202321011627
471289